HDAC-targeting epigenetic modulators for cancer immunotherapy-Reference-Cited by-同舟云学术

HDAC-targeting epigenetic modulators for cancer immunotherapy

Published:2024-02 Issue: Volume:265 Page:116129
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Cheng Binbin^ORCID,Pan Wei^ORCID,Xiao Yao^ORCID,Ding Zongbao^ORCID,Zhou Yingxing^ORCID,Fei Xiaoting^ORCID,Liu Jin^ORCID,Su Zhenhong^ORCID,Peng Xiaopeng^ORCID,Chen Jianjun^ORCID

Publisher

Elsevier BV

Reference110 articles.

1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J Immunother Cancer,2018

2. Small-molecule drugs in immunotherapy;Hao;Mini Rev. Med. Chem.,2023

3. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors;Lin;Proc. Natl. Acad. Sci. U. S. A.,2008

4. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: a focus on solid tumors;Najafi;Life Sci.,2022

5. Recent advances in small molecule based cancer immunotherapy;Cheng;Eur. J. Med. Chem.,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-based mapping of the histone-binding pocket of KDM4D using functionalized tetrazole and pyridine core compounds;European Journal of Medicinal Chemistry;2024-10

2. Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer;Journal of Medicinal Chemistry;2024-09-12

3. Exploring fatty acids from royal jelly as a source of histone deacetylase inhibitors: from the hive to applications in human well-being and health;Epigenetics;2024-09-10

4. A Live‐Cell Epigenome Manipulation by Photo‐Stimuli‐Responsive Histone Methyltransferase Inhibitor;Advanced Science;2024-09-09

5. Differential Expression of DNA Methyltransferase (DNMT1 and DNMT3), Histone Deacetylase (HDAC1 and HDAC2), and Upstream Target Regulators MiR-145 and Mir-152 among Oral Cancers;Targets;2024-08-18